Selected publications
-
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Gynecologic Oncology.
2016
Review
GET IT
Times cited: 8 -
Candidate genetic modifiers for breast and ovarian cancer risk inBRCA1andBRCA2 mutation carriers.
Cancer Epidemiology Biomarkers and Prevention.
2015
Academic Article
GET IT
Times cited: 14 -
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: A large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
Breast Cancer Research.
2014
Academic Article
GET IT
Times cited: 41 -
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
PLoS Genetics.
2014
Academic Article
GET IT
Times cited: 22